Protalix BioTherapeutics appoints independent director

In This List

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

13 Aug, 2018 | 09:21

Author Angelee Tabios
Theme Healthcare & Pharmaceuticals

Protalix BioTherapeutics Inc. appointed David Granot to its board as an independent director.

Granot brings his financial and banking knowledge to the company. He was the CEO of First International Bank of Israel Ltd. from 2001 to 2007. He also served as the CEO of the Israel Discount Bank Ltd. from 1998 to 2000.

Israel-based Protalix BioTherapeutics is a biotechnology company engaged in the development and commercialization of recombinant therapeutic proteins using ProCellEx, its proprietary plant cell-based expression system.